Haemolytic anaemia as a complication to intravenous infusion of human immunoglobulin   Not Yet Rated By Juel J, Markvardsen LH, Jakobsen J. • ProHealth.com • August 15, 2011 Tweet previous article next article A 85-year-old female treated for chronic inflammatory demyelinating polyradiculoneuropathy had three episodes of anaemia one week following treatment with large doses (2g/kg body weight) of immunoglobulin (Ig). At the final episode, she presented with haemolytic anaemia with fatigue, jaundice and loss of appetite. During the next two months anaemia was recognized in two additional cases. Subsequently, a series of twelve conseuntively studied IVIg treated patients showed a significant decrease of haemoglobin of 0.80 mmol/l 8-15 days after infusion. Haemolytic anaemia is a severe side effect that seems to be more frequent than previously recognized. It may possibly be prevented by the use of lyophilized Ig-preparations with low isohaemagglutinin titers or by slower Ig infusion rates.

previous article   Not Yet Rated next article Tweet

RELATED PRODUCT CATEGORIES

ProHealth offers a wide range of nutritional supplements for optimal health.* *These products are not intended to diagnose, treat, cure, or prevent any disease. Vitamins

DISCUSS THIS ARTICLE   (0 existing comments)
[ Be the first to comment on this article ]